SEC Filings
ORIC Expects $345.4 Million To Fund Cancer Trials Beyond Its First Late-Stage Readout
Research spending rose to $43.4 million as the prostate-cancer program advanced, while a late-stage lung-cancer trial is planned for 2027.
Oric Pharmaceuticals (ORIC) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Research spending rose to $43.4 million as the prostate-cancer program advanced, while a late-stage lung-cancer trial is planned for 2027.
SEC Filings
The drugmaker presented Phase 1b data at ESMO and said FDA talks cleared the design of its Redwood-1 trial.